Mark Sheptoff Financial Planning, LLC Nektar Therapeutics Transaction History

Mark Sheptoff Financial Planning, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 09, 2018	SELL	$46.25 - $104.45 $222,000 - $501,360	-4,800 Closed	0 $0
Q1 2018 May 08, 2018	SELL	$57.4 - $108.44 $74,620 - $140,972	-1,300 Reduced 21.31%	4,800 $510,000
Q3 2017 Nov 09, 2017	BUY	$17.79 - $24.0 $108,519 - $146,400	6,100	6,100 $146,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Mark Sheptoff Financial Planning, LLC, based on Form 13F filings with the SEC.

Stay updated on Mark Sheptoff Financial Planning, LLC with notifications on news.